Taaffe D R, Pruitt L, Reim J, Hintz R L, Butterfield G, Hoffman A R, Marcus R
Musculoskeletal Research Laboratory, Veterans Affairs Medical Center, Palo Alto, California 94304.
J Clin Endocrinol Metab. 1994 Nov;79(5):1361-6. doi: 10.1210/jcem.79.5.7525633.
Normal aging is characterized by detrimental changes in body composition, muscle strength, and somatotropic function. Reduction in muscle strength contributes to frailty and risk for fracture in the elderly. Although older adults increase muscle strength as a result of resistance exercise training, the strength gains quickly level off, with only modest increases thereafter despite continued training. To investigate whether age-related deficits in the somatotropic axis limit the degree to which muscle strength can improve with resistance training in older individuals, we conducted a double blind, placebo-controlled exercise trial. Eighteen healthy elderly men (65-82 yr) initially underwent progressive weight training for 14 weeks to invoke a trained state. Subjects were then randomized to receive either 0.02 mg/kg BW.day recombinant human GH (rhGH) or placebo, given sc, while undertaking a further 10 weeks of strength training. Sequential measurements were made of muscle strength (one repetition maximum), body composition (dual energy x-ray absorptiometry), and circulating levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3. For each exercise, strength increased for both groups (P = 0.0001) through 14 weeks of training, with little improvement thereafter. Increases in muscle strength ranged from 24-62% depending on the muscle group. Baseline plasma IGF-I concentrations were similar in both groups (mean +/- SEM, 106 +/- 9 micrograms/L), approximately half that observed in healthy young adults. In the rhGH group, IGF-I levels increased to 255 +/- 32 micrograms/L at week 15 and 218 +/- 21 micrograms/L at week 24 (P < 0.001). In the placebo group, IGF-I increased slightly to 119 +/- 6 micrograms/L at 24 weeks. IGF-binding protein-3 also increased in the rhGH group (P < 0.05). rhGH had no effect on muscle strength at any time, and no systematic difference in muscle strength was observed between groups throughout the study. Body weight did not change in either group, but lean body mass increased, and fat mass decreased (P < 0.05) in the rhGH group. Supplementation with rhGH does not augment the response to strength training in elderly men. These results suggest that deficits in GH secretion do not underlie the time-dependent leveling off of muscle strength seen with training in the elderly and provide no support for the popular view of GH as an ergogenic aid.
正常衰老的特征是身体成分、肌肉力量和生长激素功能发生有害变化。肌肉力量下降会导致老年人身体虚弱和骨折风险增加。尽管老年人通过抗阻运动训练可增加肌肉力量,但力量增长很快就会趋于平稳,此后即使继续训练,力量增加也很有限。为了研究生长激素轴与年龄相关的缺陷是否限制了老年人通过抗阻训练提高肌肉力量的程度,我们进行了一项双盲、安慰剂对照的运动试验。18名健康老年男性(65 - 82岁)最初接受了14周的渐进式重量训练以达到训练状态。然后将受试者随机分为两组,一组每天皮下注射0.02mg/kg体重的重组人生长激素(rhGH),另一组注射安慰剂,同时进行另外10周的力量训练。依次测量肌肉力量(一次重复最大值)、身体成分(双能X线吸收法)以及胰岛素样生长因子 - I(IGF - I)和IGF结合蛋白 - 3的循环水平。在14周的训练中,两组的每项运动的力量均增加(P = 0.0001),此后几乎没有改善。根据肌肉群不同,肌肉力量增加幅度在24% - 62%之间。两组的基线血浆IGF - I浓度相似(平均值±标准误,106±9μg/L),约为健康年轻人的一半。在rhGH组中,第15周时IGF - I水平升至255±32μg/L,第24周时为218±21μg/L(P < 0.001)。在安慰剂组中,24周时IGF - I略有增加至119±6μg/L。rhGH组中IGF结合蛋白 - 3也有所增加(P < 0.05)。rhGH在任何时候对肌肉力量均无影响,并且在整个研究过程中两组之间未观察到肌肉力量的系统性差异。两组体重均未改变,但rhGH组的瘦体重增加,脂肪量减少(P < 0.05)。补充rhGH并不能增强老年男性对力量训练的反应。这些结果表明,生长激素分泌不足并非老年人训练后肌肉力量随时间趋于平稳的原因,也不支持将生长激素视为一种增强体能辅助剂的普遍观点。